Treatment · United States
FDA approves Cobenfy, the first new mechanism for schizophrenia in seventy years
Bristol Myers Squibb's xanomeline/trospium combination acts on muscarinic receptors instead of dopamine — a structural shift in psychiatric pharmacology.
The FDA's approval of Cobenfy (xanomeline and trospium chloride) is the first time in more than seven decades that a schizophrenia medication has reached the market with a fundamentally different mechanism of action. It targets muscarinic acetylcholine receptors rather than blocking dopamine, which sidesteps a major source of the side-effect burden that has shaped antipsychotic care since the 1950s.
Clinicians and patient groups have framed the approval as the most significant moment in schizophrenia treatment in a generation, with caveats: long-term safety, access, and durability of response still need real-world data.
Read the FDA's official announcement for the indication, trial data, and labeling.
Mental Hum is a reading list, not a publisher. The summary above is our own editorial framing; the reporting and analysis live at the source.
If reading this brought something up for you —
Call or text 988 for the Suicide & Crisis Lifeline. See all crisis resources.